Icon

Genmab AS Stock Analysis and Price Target COMMON STOCK | Biotechnology | NSD

stockTargetAdvisor

Strong Buy

Average User
Rating
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis

USD 39.12

-0.03 (-0.08)%

USD 25.68B

0.42M

USD 36.88(-5.74%)

USD 50.00 (+27.81%)

Icon

GMAB

Genmab AS (USD)
COMMON STOCK | NSD
USD 38.28
-0.83 (-2.13%)
As of 11:49AM EST.
stockTargetAdvisor

Strong Buy

Average User
Rating
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis

USD 25.68B

USD 50.00 (+27.81%)

USD 39.12

Genmab AS Stock Forecast

USD 36.88
(-5.74%)

Based on the Genmab AS stock forecasts from 13 analysts, the average analyst target price for Genmab AS is USD 36.88 over the next 12 months. Genmab AS’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Genmab AS is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Genmab AS’s stock price was USD 39.12. Genmab AS’s stock price has changed by +0.82% over the past week, -7.69% over the past month and +13.00% over the last year.

No recent analyst target price found for Genmab AS
No recent average analyst rating found for Genmab AS

Company Overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease...Read More

https://www.genmab.com

Kalvebod Brygge 43, Copenhagen, Denmark, 1560

1,560

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

  • 0.75

  • USD 47.50

  • 4.44

  • USD 26.19

  • 3,125,028

  • USD 36.61

  • 3,288,558

  • USD 43.02

  • N/A

  • 0.17%

  • 6.96%

  • N/A

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Security Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Genmab AS (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -5.83 (-1.80%) USD82.14B 25.24 16.84
REGN
Regeneron Pharmaceuticals Inc -0.47 (-0.06%) USD80.20B 15.52 12.07
MRNA
Moderna Inc -1.76 (-1.00%) USD67.64B 6.64 5.34
ALXN
Alexion Pharmaceuticals Inc 0.00 (0.00%) USD40.34B 59.23 42.56
BNTX
BioNTech SE -0.36 (-0.25%) USD34.86B 3.27 2.14
ALNY
Alnylam Pharmaceuticals Inc -1.49 (-0.66%) USD27.73B N/A -29.42
BGNE
BeiGene Ltd -1.72 (-0.67%) USD26.95B N/A -9.58
SGEN
Seagen Inc -0.45 (-0.32%) USD25.90B 55.02 -38.86
BMRN
Biomarin Pharmaceutical Inc +1.36 (+1.18%) USD21.32B 266.74 90.91
ARGX
argenx NV ADR -2.52 (-0.66%) USD21.13B N/A -21.25

ETFs Containing GMAB

Symbol Name Weight Mer Price(Change) Market Cap
ETLI:XETRA
L&G Pharma Breakthrough U.. 3.70 % 0.49 % -0.10 (-0.93%) USD0.04B
ETLI:F
Legal & General UCITS ETF.. 3.70 % 0.49 % -0.11 (-0.95%) USD0.04B
BIOT:SW
L&G Pharma Breakthrough U.. 3.70 % 0.00 % -0.06 (-0.54%) N/A
FINT:CA
First Trust International.. 2.78 % 0.60 % 0.00 (0.00%) USD6.98M
HLTH:AU
VanEck Global Healthcare .. 2.29 % 0.45 % -0.03 (-0.29%) USD0.08B
EDGE:CA
Evolve Innovation Index F.. 1.45 % 0.55 % +0.70 (+2.39%) USD0.05B
EDGE-U:CA
Evolve Innovation Index F.. 1.45 % 0.40 % 0.00 (0.00%) N/A
DX2I:F
Xtrackers - MSCI Europe M.. 1.19 % 0.12 % +0.46 (+0.34%) USD0.05B
EL43:F
Deka MSCI Europe MC UCITS.. 1.19 % 0.30 % +0.04 (+0.30%) USD0.02B
DX2I:XETRA
Xtrackers - MSCI Europe M.. 1.19 % 0.12 % -0.46 (-0.34%) USD0.05B
EL43:XETRA
Deka MSCI Europe MC UCITS.. 1.19 % 0.30 % +0.04 (+0.37%) USD0.02B
SCID
Global X Scientific Beta .. 0.40 % 0.39 % 0.00 (0.00%) USD3.34M

Frequently Asked Questions About GMAB Stock

Based on ratings from 13 analysts Genmab AS's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 3 buy, 5 sell and 5 hold ratings.

Unfortunately we do not have enough data on GMAB's stock to indicate if its a good dividend stock.

Based on targets from 13 analysts, the average taret price for GMAB is USD 36.88 over the next 12 months. The maximum analyst target price is USD 51 while the minimum anlayst target price is USD 31.

GMAB stock's Price/Earning ratio is 30.85. Our analysis grades GMAB stock's Price / Earning ratio at F. This means that GMAB stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the NSD exchange. Based on this GMAB may be a overvalued for its sector.

The last closing price of GMAB's stock was USD 39.12.

The most recent market capitalization for GMAB is USD 25.68B.

Based on targets from 13 analysts, the average taret price for GMAB is projected at USD 36.88 over the next 12 months. This means that GMAB's stock price may go down by -5.74% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...